

CURRICULUM VITAE

NAME: Adel A. Wassef, M.D.

DATE: July, 2006

PRESENT POSITION AND ADDRESS:

— Assistant Professor

UT-Houston Harris County Psychiatric Center
2800 South MacGregor Way
Houston, TX 77021

BIOGRAPHICAL:

Date and Place of Birth	October 29, 1955, Cairo, Egypt
Citizenship	U.S. Citizen
Marital Status	Married to Denise Ingham, M.D. Three children: Michael, Christina and Audrey
Home Address	4403 Pine Blossom Trail. Houston, TX 77059 (281) 286-6878

EDUCATION:

MB, BCh	1979, Ain Shams University, Cairo, Egypt, Honor Graduate
ECFMG	1980, Score 80
VQE	1981
FLEX	1983, Score 82
Psychiatry Board Certification	1988: First part; 1989: Second part

Adel A. Wassef M.D.

PROFESSIONAL EXPERIENCE:

February, 1979 - February, 1980

Rotating Internship,
Ain Shams University Hospitals,
Cairo, Egypt

February, 1980 - February, 1981

General Practitioner,
Ministry of Health, Egypt

February, 1981 - May, 1982

Psychiatry Resident, Behman Hospital,
Cairo, Egypt

July, 1982 - July, 1984

First & Second Year Psychiatry Resident
The University of North Dakota,
Fargo, North Dakota

July, 1984 - June, 1986

Third & Fourth Year Psychiatry Resident
The University of Texas Medical Branch,
Galveston, Texas

July, 1986 - August, 1990

Assistant Professor and
Associate Medical Director of the
Psychiatric Clinical Research Center
Department of Psychiatry and Behavioral
Sciences, The University of Texas Medical
Branch, Galveston, Texas

October, 1990 - October, 1991

Staff Psychiatrist, Welborn Baptist Hospital,
Evansville, Indiana (In private practice) and
Clinical Assistant Professor (part-time)
Department of Psychiatry & Behavioral
Sciences, University of Texas Medical
Branch, Galveston, Texas

November, 1991 - July, 1994

Assistant Professor and
Associate Medical Director of the
Psychiatric Clinical Research Center,
Department of Psychiatry & Behavioral
Sciences, University of Texas Medical
Branch, Galveston, Texas

Adel A. Wassef M.D.

July, 1994 - Present Assistant Professor
Department of Psychiatry & Behavioral
Sciences, University of Texas Health Sciences,
Houston, Texas

TEACHING EXPERIENCE:

January, 1985 - June 1986 Clinical Psychopharmacology to third year
medical students

February 1986 - 1990 Introduction to Clinical Medicine
(Pre-clerkship course)

June 1986 - July, 1990 Update on Clinical Psychopharmacology
for Psychiatry Residents

July 1986 - present Clinical training of Psychiatry residents
and medical students

July 1986 - 1990 Research Diagnostic Criteria (RDC) and
Schedule for Affective Disorder and
Schizophrenia (SADS) to the Research Unit
staff, Research Assistants and interested
Psychiatry Residents

April 1989 Organizer of and teaching faculty in
a training conference on the use of ECT
for Texas State Hospital psychiatrists
(ECT: Update and Practice). Funded by TDMHMR

September 1990 - September 1994 Coordination of and major teaching responsibility
in 19 continuing education conferences on the
recognition and treatment of depression. The
conferences were attended by approximately 2000
mental health professionals from different training
backgrounds (Funded by a grant from the NIMH).

September 1990 - September 1994 Editor of the three editions of the Depression Training
Manual for the above conferences.

September 2002 - September 2004 Lectures on Advanced Psychopharmacology and Preparation for the
Psychiatric Boards Examination.

Adel A. Wassef M.D.

September 2001 - September 2003	First year Resident Class Faculty Advisor.
September 2004 - Present	Coordinator, Biological and Somatic Therapy Series for the Psychiatry Residents years one through four.
September 2004 - Present	Lectures on Antipsychotics.
September 2004 - Present	Examiner, Mock Oral Board Examination for second and fourth year residents
September 1995 – Present	Examiner, Clerkship Oral Examination for third year medical students
July 1999 – July 2002	Faculty Advisor for the first year residents

RESEARCH ACTIVITY:

2003-present: Semantic Priming in Schizophrenia. Funded by the National Institute of Health. Principal Investigator: Ann Sereno, Ph.D

2002-2004: Neural Correlates of Cognition in Schizophrenia. RO1 MH61927-01A2 05/1/02-04/31/05 5% effort. Principal Investigator: J.L. Steinberg. NIH/NIMH, Total direct costs: \$625,000.

2002-2004: Functional Magnetic Resonance Imaging of Working Memory Abnormalities in Schizophrenic Patients. Dana Clinical Hypotheses in Neuroscience Research Program 02/01/00 - 12/31/01 5% effort. Principal Investigator: J.L. Steinberg. The Charles A. Dana Foundation. Total direct costs: \$99,534.

1999-present: Delayed memory and functional MRI studies in schizophrenia. Funded by the National Institute of Health.

February 2001-August 2002: Org 5222 long term safety in schizophrenia: Funded by Organon Inc. Principal Investigator: A Wassef, MD

July 2001- March 2002: Org 5222 in acute schizophrenia: Funded by Organon Inc. Principal Investigator: A Wassef, MD

February 2000- February 2001: Divalproex in Schizophrenia. Funded by Abbott Laboratories. Principal Investigator: A Wassef, MD. Also consulted with Abbott Labs on protocol design and provided the preliminary data needed for study design and implementation

November 1998 – August 1999: Principal Investigator of "A Double-blind, Randomized Comparison of the Safety and Efficacy of Iloperidone in Acute Schizophrenic Patients." Funded by Novartis Pharmaceuticals.

November 1998 – August 1999: Principal Investigator of "A Double-blind, Randomized Assessment of the Long-term Safety of Iloperidone in Schizophrenia." Funded by Novartis Pharmaceuticals.

Adel A. Wassef M.D.

January 1999 – October 1999: Principal Investigator of "A Double-blind, Randomized Comparison of the Safety and Efficacy of EMD 128-130 in Schizophrenic Patients." Funded by Merck KGaA. – Germany

January 1998- February 2000: EMD128 130 in acute schizophrenia. Funded by Merck KGaA – Germany

January 1997 - present: Principal Investigator of "An Open-Label Assessment of the Long-term Safety of Sertindole." Funded by Abbott Laboratories. – Germany

April 1996– March 1998: Principal Investigator of "A Double-blind, Randomized Comparison of the Safety and Efficacy of Sertindole and Risperidone in Treatment Resistant Schizophrenic Patients." Funded by Abbott Laboratories.

August 1994 - March 1998: Co-principal Investigator of a study entitled "A Double-blind, Placebo-Controlled, Dose-Response Comparison of the Safety and Efficacy of Three Doses of Sertindole and three doses of Haldol in Schizophrenic Patients." Funded by Abbott Laboratories.

September 1990 - present: Principal Investigator of "Short-term Training Conferences on Depressive Disorders." Funded by the National Institute of Mental Health (NIMH) for three years (\$125,000/year). Michael O'Boyle, M.D., was director during the period in which I was in private practice in Evansville until my return to the University on full-time basis.

April 1993 – July 1995: Principal Investigator of a study entitled "Safety and Efficacy of Depakote in Prevention of Mania in Patients with Bipolar Disorder: A One Year Maintenance Study Comparing Depakote, Lithium and Placebo." Funded by Abbott Laboratories.

January 1994 - July 1995: Principal Investigator of a study entitled " Factors Which Affect Specialty Choice in Medical Students."

March 1993 - July 1995: Principal Investigator of a study entitled "Efficacy of Volunteer Facilitated Peer Support Groups in High School Adolescents."

October 1987 - July 1995: Principal Investigator of a study entitled "Efficacy of Valproic Acid in Acute Exacerbation of Chronic Schizophrenia."

October 1991 - July 1995: Principal Investigator of a study entitled "Efficacy of Valproic Acid in Neuroleptic-Resistant Schizophrenia."

July 1993 - July 1995: Co-principal Investigator of a study entitled "A Multicenter Study Comparing Seroquel and Haloperidol in the Treatment of Hospitalized Subjects with Acute Exacerbation of Chronic or Subchronic Schizophrenia." Funded by Zeneca Pharmaceutical.

July 1993 - May 1994: Co-principal Investigator of a study entitled "Fixed Dose Olanzapine Versus Placebo in the Treatment of Schizophrenia." Funded by Eli Lilly Pharmaceuticals.

Adel A. Wassef M.D.

September 1987 - September 1989: Participant in the preparation of an NIMH grant proposal to study lymphocyte TSH production in major depression. Principal Investigators: D.V. Harbour, Ph.D. and W.J. Meyer, III, M.D.

September 1987 - September 1990: Participant in the preparation and implementation of a study of glucocorticoid receptor characteristics and function in major depression. Principal Investigator: W J. Meyer, III, M.D. Funded by the NIMH for \$220,000.

June 1986 - 1988: Principal Investigator of a study entitled "Efficacy and Safety of Etoposide in Major Depression". Funded by McNeil Pharmaceutical Company.

April 1985 - July 1988: Participant in a study of the leukocytes ACTH production in depression. In collaboration with R.M. Rose, M.D., E.M. Smith, Ph.D., and W.J. Meyer, III, M.D.

April 1985 - 1990: Participant in a study of the lymphocyte glucocorticoid receptor characteristics in correlation with adrenal axis changes in depression. In collaboration with R.M. Rose, M.D. and W.J. Meyer, III, M.D.

July 1985 - 1987: Participant in a study of brain water metabolism in depression using magnetic resonance imaging (MRI). Principal Investigator: T. Kent, M.D.

July 1985 - 1989: Participant in a study of the lymphocyte glutamine synthetase inducibility by dexamethasone in psychiatric disorders. In collaboration with R.M. Rose, M.D., E. Brad Thompson, M.D., W. J. Meyer, III, M.D., and T. McCarthy, B.S.

June 1985 - August 1985: Participant in a study to determine the long term efficacy and side effects of BW234U, a new antipsychotic. Principal Investigator: S. Bryant, Ph.D. Funded by Burroughs-Wellcome Corporation.

COMMITTEE RESPONSIBILITIES:

UT Health Sciences Committees: Pharmacy and Therapeutics Committee. Currently Committee Chairman

Quality Review Board
Executive Committee
Policies and Procedures Committee
Committee for Selection of Clinical Management Software
Medical Director Search Committee

UTMB University Committees: Introduction to Clinical Medicine Committee
Disaster Relief Committee
Undergraduate Committee
Residency Training Committee
Private Practice Committee
Patient Rights Committee

Adel A. Wassef M.D.

Inpatient Unit Reorganization Task Force

LICENSURE INFORMATION:

Texas license

Elected Positions

Medical Staff President Elect, Harris County Psychiatric Center, 1997

Boards and Advisory Committees:

Advisory Board Member, Drug Information and Outcome Center: 1999 – 2001

Psychosis Studies Consultant to Abbott Laboratories: 1999 – 2002

PUBLICATIONS:

Published:

A. Articles:

1. Harbour, D.V., Anderson, A., Farrington, J., Wassef, A., Smith, E.M., and Meyer, W.J. III. Decreased lymphocyte TSH responsiveness in patients with major depression. *Biol. Psychiatry*, 23:797-806, 1988.
2. Wassef, A., Watson, D., Morrison, P., Bryant, S. and Flack, J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. *J. of Clinical Psychopharmacology*, 9:45-48. 1989.
3. Wassef, A., Smith, E.M., Rose, R.M., Gardner, R., Nguyen, H., and Meyer, W.J. III. Mononuclear glucocorticoid receptor binding-characteristics and down-regulation in major depression. *Psychoneuroendocrinology*, 15(1): 59-68, 1990.
4. Wassef, A., O'Boyle, M., Gardner, R., Rose, R.M., Brown, A., Harris, A., Nguyen, H. and Meyer, W.J. III. Glucocorticoid receptor binding in three different cell types in major depression: Lack of evidence of receptor binding defect. *Prog. Neuro-Psychopharmacol. Biol. Psychiat.* 16(1): 65-78, 1992.
5. Paniagua, F., Wassef, A., Linares, S. and O'Boyle, M. What is a difficult mental health case? An empirical study of relationships among domain variables. *Journal of Contemporary Psychotherapy* 23: 79-100, 1993.
6. Ramirez, S., Wassef, A., Paniagua, F., Linskey, A. and O'Boyle, M. Perceptions of mental health providers concerning cultural factors in the evaluations of Hispanic children and adolescents. *Hispanic Journal of Behavioral Sciences* 16: 28-42, 1994.
7. Wassef, A., Ingham, D., Lassiter-Collins, M. and Mason, G. In search of effective programs to address students' emotional distress and behavioral problems: Part I: Defining the problem. *Adolescence* 30(119): 523-538, 1995.
8. Wassef, A., Lassiter-Collins, M., Ingham, D. and Mason, G. In search of effective programs to address students' emotional distress and behavioral problems: Part II: Critique of community and school based programs. *Adolescence* 30(120), 757-777, 1995.
9. Wassef, A., Mason, G., Lassiter-Collins, M., O'Boyle, M. and Ingham, D. In search of effective programs to address students' emotional distress and behavioral problems: Part III: Student assessment of school-based support groups. *Adolescence* 31 (121), 2-16, 1996 (Spring).
10. O'Boyle, M., Paniagua, F., Wassef, A. and Holzer, C. Training health professionals in the recognition and treatment of depression. *Psychiatric Services* 46: 616-618, 1995.

12. Wassef, A., Mason, G., Lassiter Collins, M., VanHaalen, J., and Ingham, D. Effectiveness of One-Year Participation in School-Based Volunteer-Facilitated Peer Support Groups. *Adolescence* 33 (129) 91:97, 1998 (Spring).
13. Dougherty, D., Steinberg, J., Wassef, A., Medearis, D., Cherek, D., and Moeller, G. Immediate Versus Delayed Visual Memory Task Performance Among Schizophrenic Patients and Normal Controls. *Psychiatry Research*. 79(3):255-65, 1998 Jul 13.
14. Wassef, A., Dott, S., Harris, A., Brown, A., O'Boyle, M., Meyer, W., and Rose, R. Critical Review of GABA-ergic Drugs in the Treatment of Schizophrenia. *J. of Clinical Psychopharmacology* 19(3) 222-232, 1999
15. Bowden, C., Swann, A., Calabrese, J., McElroy, S., Morris, D., Petty, F., Wassef, A., Hirschfeld, R., Gyulai, L. Maintenance Clinical Trials in Bipolar Disorder: Design Implications of the Divalproex-Lithium-Placebo Study. *Psychopharmacology Bulletin* 33(4):693-699, 1997
16. Wassef A., Dott, S., Harris A., Brown A., O'Boyle, M., Meyer, W.J. III, and Rose, R. Randomized, Placebo-controlled Pilot study of Divalproex Sodium in the Treatment of Acute Exacerbations of Chronic Schizophrenia. *J. of Clinical Psychopharmacology* 20 (3):357-361, 2000.
17. Bowden, C., Calabrese, J., McElroy, S., Gyulai, L., Wassef, A., Petty, F., et al. Randomized, Placebo-Controlled Trial of Divalproex Sodium Versus Lithium in Maintenance Therapy of Bipolar Disorder. *Archives of Gen. Psychiatry* 57 (5):481-489, 2000
18. Wassef A., Hafiz N, S., Hampton D., Molloy M. Divalproex Sodium Augmentation of Haloperidol in Hospitalized Patients with Schizophrenia: Clinical and Economic Implications. *J. of Clinical Psychopharmacology* 21(1) 21-26, 2001
19. Lachar, D., Bailey, S., Rhoades, H., Espadas, A., Aponte, M., Cowan, K., Gummattira, P., Kopecky, C., Wassef, A. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. *Psychological Assessment* 13(3):384-95, 2001.
20. Casey, D., Daniel, D., Wassef, A., Tracy, K., Wozniak, P., Sommerville, K. For the Depakote Psychosis Group. Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia. *Neuropsychopharmacology* 28, 182-192, 2003 Jan.
21. Gyulai L., Bowden CL., McElroy SL., Calabrese JR., Petty F., Swann AC., Chou JC., Wassef A., Risch CS., Hirschfeld RM., Nemeroff CB., Keck PE Jr., Evans DL., Wozniak PJ. Maintenance efficacy of divalproex in the prevention of bipolar depression. *Neuropsychopharmacology*. 28(7):1374-82, 2003 Jul.
22. Wassef, A., Baker, J., Kochan, L.D. GABA and Schizophrenia: A Review of Basic Science and Clinical Studies.[Review]. *J Clinical Psychopharmacology* 23(6):601-640, 2003, Dec.

Adel A. Wassef M.D.

23. Reply: Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia. Casey D.E, Daniel D.G., Wassef A.A., Tracy K. A., Wozniak P., Sommerville K.W. *Neuropsychopharmacology* 28, 2052-2053, 2003, Nov.
24. Lopez L.M., Wassef A.A., Molloy M.S., Williams N.G. Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.[Letter] *Neuropsychopharmacology* 29(6):1217; author reply 1218-20, 2004 Jun.
25. Pettit J.W., Averill P.M., Wassef A.A., Gruber N.P., Schneider L. Ratings of early major depressive disorder symptom change during a brief psychiatric hospitalization. *Psychiatric Quarterly* 76(1):33-48, 2005
26. Wassef A.A., Winkler D.E., Roache A.L., Abobo V.B., Lopez L.M., Averill J.P., Mian A.I., Overall J.E. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. *American Journal of Psychiatry* 162(2):330-9, 2005 Feb.
27. Patricia M. Averill, Adel A. Wassef. Who receives antidepressants and what impact do they have? An acute-care study. *Psychiatric Quarterly*, 2006, June
28. Babin, S.L., Wassef, A.A., Sereno, A.B. Schizophrenic patients exhibit hyper-reflexivity in a semantic categorical priming task. *Journal of Neurolinguistics*. Accepted.

B. Abstracts:

1. Wassef, A., Meyer, W.J. III, Smith, E.M., McCarty, T., Thompson, E.B., and Rose, R.M. Leukocyte glucocorticoid related events in major depression: evidence of a partial post-receptor binding defect. *The American College of Neuropsychopharmacology Annual Meeting*. 1986.
2. Kent, T.A., Amparo, E.G., Johnson, R.F., Wassef, A., and Rose, R.M. Brain water content in depression. An MRI study. *New Research Abstracts, American Psychiatric Association*, 1986.
3. Anderson, A., Farrington, J., Harbour, D., Wassef, A., Smith, E.M., and Meyer, W.J. III. Decreased lymphocyte TSH responsiveness in patients with major depression. *National Student Research Forum* 1987.
4. Harbour, D.V., Anderson, A., Farrington, J., Wassef, A., Smith E.M., and Meyer, W.J. III. Decreased mononuclear leukocyte TSH secretion in patients with major depression. *Society for Neuroscience*, 1987; 13:614.
5. Meyer, W.J. III, Harbour, D.V., Gardner, R., Wassef, A., Smith, E.M., and Rose, R.M. The Lymphocyte: an *in vitro* model of the anterior pituitary function. *The American College of Neuropsychopharmacology 27th Annual Meeting*. 1988.

6. Wassef, A., O'Boyle, M., Rose, R.M., Brown, A., Harris, A., Nguyen, H., and Meyer, W.J. III. Glucocorticoid receptor binding in three different cell types in major depression disorder: Lack of evidence of receptor binding defect. *The American College of Neuropsychopharmacology 28th Annual Meeting*, 1989.
7. Meyer, W.J. III, Harbour, D.V., Gardner, R., Wassef, A., and Smith E.M. Correlation of TRH stimulation of *in vitro* production of TSH by lymphocytes with *in vivo* TRH pituitary testing. *Society for Neuroscience Abstracts* 15:719, Abstract #291.8, 1989.
8. Wassef, A., Watson, D., Meyer, W.J. III, O'Boyle, M., Dott, S., Harris, A. and Brown, A. Combined valproic acid-haloperidol treatment of schizophrenia: preliminary results. *ACNP Annual Meeting*, 1990.
9. O'Boyle, M., Wassef, A. and Schweitzer, L. Personality disorders and multiple substance use. *American Psychiatric Association*, 1992.
10. Ramirez, S., Wassef, A., Paniagua, F. and Linskey, A. The significance of culture in evaluation of psychopathology in minority individuals. *Texas Psychological Association*, November, 1993.
11. Ramirez, S., Morgan, V, Duffy, J., Paniagua, F., Wassef, A. and Linskey, A. The consideration of cultural factors in the evaluation of Hispanic children and adolescents. *The National Association for School Psychologists Convention in Chicago*, March, 1995.
12. Wassef, A., Dott, S. Russell, J, Meyer, W, Lassiter Collins, M. Abrahams, N., Rose, R. and Santy, P. Augmentation of Neuroleptic Therapy with Divalproex Sodium in Patients with Treatment-Resistant Schizophrenia: Preliminary Report. *American Collage of Neuropsychopharmacology*, December, 1996 San Juan, Puerto Ricco.
13. Steinberg, J., Hatfield, G., Dougherty, D., Narayana, P., Kramer, L., Moeller, F., Shah, N., and Wassef, A. FMRI of Schizophrenic and Normal Subjects During Performance of a Working Memory Task. *International Society of Magnetic Resonance in Medicine*, 1998, Sydney, Australia.
14. Daniel, D., Wassef, A., Tracy, K., Jiang, P., Sommerville, K., Casey, D. Divalproex Enhances Antipsychotic Treatment of Recently Hospitalized Schizophrenia Patients. *NCDEU*, 2002.
15. Citrome, L., Daniel, D., Wassef, A., Tracy, K., Wozniak, P., Casey, D. Antipsychotic Monotherapy versus Combination Treatment with Valproate in Hospitalized Patients with Acute Schizophrenia: A Double-Blind Multi-Center Study. *APA*, 2002.
16. Casey, D., Tracy, K., Daniel, D., Wassef, A., Tran-Johnson, T., Rosenthal, M., Wozniak, P., Sommerville, K. Divalproex Sodium Enhances Antipsychotic-Induced Improvement in Schizophrenia. *ACNP*, 2001.
17. Daniel, D., Tran-Johnson, T., Rosenthal, M., Wassef, A., Tracy, K., Wozniak, P., Walch, J., J. Fugate J., Casey D. Divalproex Sodium Enhances Antipsychotic-Induced Improvement in Schizophrenia. *IPS*, 2001.

18. Wassef, A., Casey, D., Daniel, D., Citrome, L. Tracy, K., Wozniak, P., Walch, J., Fugate, J., Divalproex Sodium Augments Antipsychotic-Induced Improvement in Acute Schizophrenia: US Psychiatric Congress, 2001.
19. Daniel, D., Tran-Johnson, T., Rosenthal, M., Wassef, A., Tracy K., Wozniak, P., Walsh, J., Fugate, J., Casey, D. Divalproex Sodium Enhances Antipsychotic-Induced Improvement in Schizophrenia. APA Institute of Psychiatric Services, October 10-14, 2001, Orlando, Florida.
20. Steinberg, J., Dougherty, D., Narayana, P., Kramer, L., Wassef, A., Occhiline, V., Le, Y., Shah, N. Event-related FMRI of working memory in schizophrenic and control subjects. The 8th International Conference on Functional Mapping of the Human Brain, June 2-6, 2002, Sendai, Japan. NeuroImage, Vol. 16, No. 2, 10340.
21. Steinberg J.L., Narayana P.A., Dougherty D.M., Kramer L.A., Wassef A.A., Le Y.L., Occhiline V.B., Shah N.N.. Parametric event-related FMRI of working memory in schizophrenic and healthy control subjects, Program No. 705.4. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online. Poster presented at the Society for Neuroscience 32nd Annual Meeting, Orlando, Florida, Nov. 2-7, 2002.
22. Steinberg J.L., Narayana P.A. Dougherty D.M. Kramer L.A. Wassef A.A., and Moeller F.G. FMRI of working memory in schizophrenia. Paper presented at the 20th Annual Houston Conference on Biomedical Engineering Research, Houston, TX. April 4, 2003. (Invited Presentation).
23. Abobo V., Winkler D., Obiozor L., Brown M., Wassef A. Ameliorating atypical antipsychotic prescribing pattern in a teaching county psychiatric hospital. American Society of Health Care Systems Midyear Clinical Meeting, New Orleans, December 7-11, 2003 (P-192-R).
24. Abobo V., Winkler D., Averill J.P., Pazzaglia P., Wassef A. Atypical antipsychotic prescribing pattern in an urban free-standing teaching psychiatric county hospital. American Society of Health Care Systems Midyear Clinical Meeting, New Orleans, December 7-11, 2003 (P171-E).
25. Babin S.L., Wassef A.A., Briand K.A., Sereno A.B. (2003) Semantic priming in schizophrenia: evidence for reflexive but not voluntary priming. 33rd Annual Meeting Society for Neuroscience Abstracts, 2003.
26. Steinberg J.L., Moeller, F.G. Dougherty D.M., Ponnada A., Narayana P.A. Kramer L.A., Wassef A.A. Event Related FMRI of Working Memory in Schizophrenic Patients and Healthy Control Subjects. The Human Brain Mapping meeting in Budapest Hungary, June 13-17, 2004.
27. Babin S.L., Wassef A.A., Briand K.A., Sereno A.B. (2004) Evidence for hyper-reflexivity on a categorical semantic priming task in schizophrenics. 12th World Congress of Psychophysiology, Chalkidiki, Greece. International Journal of Psychophysiology (54)1-2 pgs. 102-103
28. Babin S.L., Wassef A.A., Briand K.A., Sereno A.B. (2004) Evidence for reflexive but not voluntary attentional priming deficits in schizophrenia. 34th Annual Meeting Society for Neuroscience Abstracts.

Adel A. Wassef M.D.

29. Steinberg, J. L., Wassef, A. A., Moeller, F. G., Kramer, L. A., Dougherty, D. M., Occhiline, V. B., Guerra, S. L., Narayana, P. A. (2006) FMRI of Working Memory in Schizophrenia and Normal Controls. Abstract Number: 2577. Human Brain Mapping Meeting, Florence Italy, June,.
30. Babin, S.L., Wassef, A.A., and Sereno, A.B. (2005). The effects of Haldol, Zyprexa, and Abilify on reflexive and voluntary eye movements. The 35th Society for Neuroscience Abstracts

Book Chapters:

1. Wassef A., Morgan V., Ramirez S., and Lassiter-Collins, M. Group Programs for Adolescent Serious Emotional Disturbance and Non-Serious Emotional Disturbance Students. In: Contemporary Interdisciplinary Interventions for Children with Emotional/Behavioral Disorders. Eds. Sabatino D. and Brooks B. Carolina Academic Press, Durham, North Carolina. 1998; 763-780.
2. Wassef A. GABA-ergic Drugs in Schizophrenia. In: Role of Neurotransmitter Receptors in Actions of Antipsychotic Medications. Ed. Michael Libow. CRC Press, LLC. 1999.

Presentations:

1. Atypical antipsychotics: Buy, Sell or Hold. Harris County Network of Mental Health Providers, Houston, Texas, March 20, 1998.
2. Preliminary Studies on the Efficacy of Valproate in Schizophrenia. The Abbott Laboratory Investigators Meeting, Phoenix, Arizona, January 28, 2000.
3. An Update on the Use of Valproic Acid in Psychosis. The Houston Research Study Group, Houston, Texas, May, 2000.
4. The Role of Valproate in Schizophrenia. Grand Rounds at the University of East Tennessee, October 13, 2000.
5. GABAergic Compounds in Schizophrenia: Theoretical and Clinical Implications. Annual Physician Meeting of Intracare Hospital, Houston, June 26, 2002.
6. The Role of GABA in Schizophrenia. Mental Health Mental Retardation Authority of Harris County Continuing Medical Education Seminar. March 20, 2002.
7. Invited Speaker at The Psychiatric Institute, University of Illinois at Chicago (UIC). Invited by Erminio Costa, MD to present a lecture on the Integration between Basic Sciences and clinical studies of valproic acid in schizophrenia. March 6, 2004.
8. GABA in Schizophrenia, Theoretical and Clinical Implications. Presented at Grand Rounds, The University of Texas Health Sciences, Houston in September 8, 2004.

Adel A. Wassef M.D.

Awards and Honors:

1. Instructor of the Year Award June, 1999
2. Instructor of the Year Award June, 2000
3. The Dean's Excellence in Teaching Award March, 2003
4. The Dean's Excellence in Teaching Award March, 2006
5. Instructor of the Year Award June, 2006